EMAGIN CORPORATION (EMAN)

US29076N2062 - Common Stock

2.07  +0.06 (+2.99%)

After market: 2.07 0 (0%)

Fundamental Rating

1

Taking everything into account, EMAN scores 1 out of 10 in our fundamental rating. EMAN was compared to 107 industry peers in the Semiconductors & Semiconductor Equipment industry. Both the profitability and financial health of EMAN have multiple concerns. EMAN has a expensive valuation and it also scores bad on growth.



1

1. Profitability

1.1 Basic Checks

In the past year EMAN has reported negative net income.
In the past year EMAN has reported a negative cash flow from operations.
In the past 5 years EMAN always reported negative net income.
In the past 5 years EMAN always reported negative operating cash flow.

1.2 Ratios

EMAN has a Return On Assets of -18.20%. This is amonst the worse of the industry: EMAN underperforms 83.02% of its industry peers.
The Return On Equity of EMAN (-114.25%) is worse than 88.68% of its industry peers.
Industry RankSector Rank
ROA -18.2%
ROE -114.25%
ROIC N/A
ROA(3y)-11.89%
ROA(5y)-17.55%
ROE(3y)-34.55%
ROE(5y)-36.21%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

EMAN has a Gross Margin of 26.24%. This is amonst the worse of the industry: EMAN underperforms 80.19% of its industry peers.
EMAN's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for EMAN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 26.24%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.34%
GM growth 5Y7.77%

2

2. Health

2.1 Basic Checks

EMAN does not have a ROIC to compare to the WACC, probably because it is not profitable.
EMAN has more shares outstanding than it did 1 year ago.
EMAN has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, EMAN has an improved debt to assets ratio.

2.2 Solvency

EMAN has an Altman-Z score of -3.59. This is a bad value and indicates that EMAN is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -3.59, EMAN is doing worse than 81.13% of the companies in the same industry.
A Debt/Equity ratio of 1.59 is on the high side and indicates that EMAN has dependencies on debt financing.
EMAN's Debt to Equity ratio of 1.59 is on the low side compared to the rest of the industry. EMAN is outperformed by 87.74% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.59
Debt/FCF N/A
Altman-Z -3.59
ROIC/WACCN/A
WACC12.71%

2.3 Liquidity

EMAN has a Current Ratio of 2.06. This indicates that EMAN is financially healthy and has no problem in meeting its short term obligations.
EMAN has a Current ratio of 2.06. This is in the lower half of the industry: EMAN underperforms 75.47% of its industry peers.
EMAN has a Quick Ratio of 1.16. This is a normal value and indicates that EMAN is financially healthy and should not expect problems in meeting its short term obligations.
EMAN's Quick ratio of 1.16 is on the low side compared to the rest of the industry. EMAN is outperformed by 81.13% of its industry peers.
Industry RankSector Rank
Current Ratio 2.06
Quick Ratio 1.16

2

3. Growth

3.1 Past

The earnings per share for EMAN have decreased strongly by -650.00% in the last year.
Looking at the last year, EMAN shows a small growth in Revenue. The Revenue has grown by 0.19% in the last year.
Measured over the past years, EMAN shows a small growth in Revenue. The Revenue has been growing by 6.74% on average per year.
EPS 1Y (TTM)-650%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-550%
Revenue 1Y (TTM)0.19%
Revenue growth 3Y4.54%
Revenue growth 5Y6.74%
Revenue growth Q2Q-30.79%

3.2 Future

Based on estimates for the next years, EMAN will show a very negative growth in Earnings Per Share. The EPS will decrease by -177.41% on average per year.
The Revenue is expected to grow by 2.91% on average over the next years.
EPS Next Y-1648.97%
EPS Next 2Y-177.41%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-25.5%
Revenue Next 2Y2.91%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EMAN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EMAN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A cheap valuation may be justified as EMAN's earnings are expected to decrease with -177.41% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-177.41%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for EMAN!.
Industry RankSector Rank
Dividend Yield N/A

EMAGIN CORPORATION

NYSEARCA:EMAN (10/17/2023, 7:04:00 PM)

After market: 2.07 0 (0%)

2.07

+0.06 (+2.99%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSemiconductors & Semiconductor Equipment
GICS IndustrySemiconductors & Semiconductor Equipment
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap172.20M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -18.2%
ROE -114.25%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 26.24%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.38
Health
Industry RankSector Rank
Debt/Equity 1.59
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.06
Quick Ratio 1.16
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-650%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-1648.97%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)0.19%
Revenue growth 3Y4.54%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y